SLMAP
Sarcolemmal membrane-associated protein
Protein Summary
May play a role during myoblast fusion. This gene encodes a component of a conserved striatin-interacting phosphatase and kinase complex. Striatin family complexes participate in a variety of cellular processes including signaling, cell cycle control, cell migration, Golgi assembly, and apoptosis. The protein encoded by this gene is a coiled-coil, tail-anchored membrane protein with a single C-terminal transmembrane domain that is posttranslationally inserted into membranes. Mutations in this gene are associated with Brugada syndrome, a cardiac channelopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]
- ENST00000295951
- ENSP00000295951
- ENSG00000163681
- ENST00000295952
- ENSP00000295952
- ENST00000383718
- ENSP00000373224
- ENST00000428312
- ENSP00000398661
- ENST00000449503
- ENSP00000412945
- KIAA1601
- SLAP
- SLAP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 0.98 | ||
transcription factor binding site profile | 0.82 | ||
histone modification site profile | 0.8 | ||
transcription factor perturbation | 0.74 | ||
tissue | 0.69 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 36.32 (req: < 5)
Gene RIFs: 3 (req: <= 3)
Antibodies: 65 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 36.32 (req: >= 5)
Gene RIFs: 3 (req: > 3)
Antibodies: 65 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0